The increase was primarily driven by headcount growth to support our business expansion. RMB216.2 million for the same period in 2020. Operating expenses were RMB262.6 million (US$40.8 million) for the three months ended September 30, 2021, representing a 21.5% increase from Gross margin was 72.3% for the three months ended September 30, 2021, compared to 73.9% for the same period in 2020. Gross profit was RMB91.6 million (US$14.2 million) for the three months ended September 30,Ģ021, which was remained relatively stable compared to the same period in 2020.
Three months ended September 30, 2021, representing a 79.3% increase from RMB2.3 million for the same period in 2020, primarily attributable to increased testing performed for our pharma customers and growth in companion diagnosticsĬost of revenues was RMB35.0 million (US$5.4 million) for the three months ended September 30,Ģ021, representing an 8.4% increase from RMB32.3 million for the same period in 2020, which was generally in line with the Companys continued business growth. Revenue generated from pharma research and development services was RMB4.1 million (US$0.6 million) for the (US$6.8 million) for the three months ended September 30, 2021, representing a 37.9% increase from RMB31.7 million for the same period in 2020, driven by in-hospital testing volume growth. Revenue generated from in-hospital business was RMB43.7 million Months ended September 30, 2021, representing a 9.7% decrease from 8,644 for the same period in 2020. Months ended September 30, 2021, representing a 12.3% decrease from RMB89.9 million for the same period in 2020, primarily attributable to a decrease in the number of patients tested in the central laboratory channel to 7,808 for the three Revenue generated from central laboratory business was RMB78.8 million (US$12.2 million) for the three RMB126.6 million (US$19.7 million) for the three months ended September 30, 2021, representing a 2.2% increase from RMB123.9 million for the same period in 2020, or a 0.5% sequential decrease from RMB127.3 millionįor the three months ended June 30, 2021. Over 11,000 tests during the third quarter of 2021, despite the negative COVID-19 impact in August. The volume of in-hospital NGS-based test kits grew 37% year-over-year to Testing, with industry-leading scale and growth rate. Food and Drug Administration (FDA) for the Phase I/II clinical study.Ĭontinued execution of our strategic shift towards more in-hospital For instance, in early November, we announced further collaboration with IMPACT Therapeutics where our Guangzhou and California laboratories would provide testing services inĬonnection with IMPACT Therapeutics development of its ATR inhibitor IMP9064, which has received the Investigational New Drug (IND) clearance from the U.S. Pathologists (CAP)-accredited laboratory in California continue to grow. Pharma projects involving our Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American The total value of new contracts we entered intoĭuring the nine months ended September 30, 2021 amounted to RMB144 million, which is approximately 4.5 times of the new contract value signed in full-year 2020. Pharma service contract backlog continues to build rapidly. Number of pilot hospitals in China for the commercialization of our 6-cancer early detection product, and will focus on customer education and contracting more hospitals.ĩ-cancer early detection product development read-out in the first half of 2022, with potential performance improvement over that of our GUANGZHOU, China, November 16, 2021≻urning Rock Biotech Limited (NASDAQ: BNR, the ∼ompany or ∻urning Rock), a companyįocused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2021.Ħ-cancer product: we have successfully signed contracts with a small Burning Rock Reports Third Quarter 2021 Financial Results
0 kommentar(er)
